| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the National Jewish Center for Immunology and Respiratory Medicine, Denver
Seventeen commercially available jet nebulizers from 15 commercial sources were studied (Acorn-I, Acorn-II, AquaTower, AVA-NEB, Cirrhus, Dart, DeVilbiss 646, Downdraft, Fan Jet, MB-5, Misty Neb, PARI LC JET, PARI-JET, Salter 8900, Sidestream, Updraft-II, Whisper Jet). All nebulizers were filled with 2 ml of saline solution plus 0.5 ml of albuterol and powered with the same source (DeVilbiss PulmoAide). We compared total output (TO), time for total output (TTO), and percent output in respirable range (PORR). The TO was obtained by weighing before nebulization and at the point of eightfold decline in output. The ITO was calculated from initiation of nebulization to the point of eightfold decline in output. The PORR was measured by a laser particle analyzer in continuous nebulization to the same point of abrupt drop in output. The TO varied from 0.98 To 1.86 ml (p<0.0001) with the Acorn-I, Acorn-II, Updraft-II, and Sidestream, significantly greater than the others (p<0.05). The TTO varied from 2.28 to 20.95 min (p<0.0001). The AquaTower, PARI LC JET and PARI-JET, DeVilbiss, and Dart were significantly shorter than the others (p<0.05). The PORR varied from 21.89 to 71.95 percent (p<0.0001). The Sidestream was significantly greater than all others (p<0.05). The PARI LC JET and PARI-JET were, in turn, significantly greater than the remaining models (p<0.05). To combine these characteristics, we calculated respirable particle delivery rate (RPDR) by dividing TO by TTO and multiplying by PORR. The RPDR varied from 0.03 ml/min to 0.26 ml/min (p<0.0001). The PARI LC JET (0.24 ml/min) and the PARI-JET (0.26 mg/min) had a RPDR that was significantly greater than the other models except the AquaTower, which, however, had a markedly variable performance. The Sidestream (0.19 mg/ml) did not differ significantly from the above group, nor from the DeVilbiss and Downdraft. All other models had significantly lower outputs (p<0.05). We conclude that the output characteristics of commercial nebulizers vary greatly and will impact on the time required for treatment as well as the total amount of drug delivered to the lungs.
Key Words: aerosol therapy • jet nebulizers
Submitted on November 8, 1993
Accepted on April 19, 1994
This article has been cited by other articles:
|
|
 |
|
  M. B. Shirk, K. R. Donahue, and J. Shirvani Unlabeled uses of nebulized medications. Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1704 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Inhalation devices Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Reychler, A. Keyeux, C. Cremers, C. Veriter, D. O. Rodenstein, and G. Liistro Comparison of Lung Deposition in Two Types of Nebulization: Intrapulmonary Percussive Ventilation vs Jet Nebulization Chest, February 1, 2004; 125(2): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Verbanck, D. Schuermans, W. Vincken, and M. Paiva Saline aerosol bolus dispersion. I. The effect of acinar airway alteration J Appl Physiol, May 1, 2001; 90(5): 1754 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Crapo Guidelines for Methacholine and Exercise Challenge Testing---1999 . THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY WAS ADOPTED BY THE ATS BOARD OF DIRECTORS, JULY 1999 Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 309 - 329. [Full Text]
|
|
|
|
|
|
D. R. Hess, F. L. Acosta, R. H. Ritz, R. M. Kacmarek, and C. A. Camargo Jr The Effect of Heliox on Nebulizer Function Using a {beta}-Agonist Bronchodilator Chest, January 1, 1999; 115(1): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
